Provention Bio Inc (NASDAQ:PRVB) Director Anthony Digiandomenico purchased 10,000 shares of the firm’s stock in a transaction dated Thursday, June 20th. The stock was acquired at an average price of $10.96 per share, with a total value of $109,600.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Anthony Digiandomenico also recently made the following trade(s):
- On Monday, June 17th, Anthony Digiandomenico acquired 25,000 shares of Provention Bio stock. The shares were purchased at an average price of $12.16 per share, with a total value of $304,000.00.
Provention Bio stock traded up $0.73 during midday trading on Friday, reaching $12.00. 292,729 shares of the stock traded hands, compared to its average volume of 552,451. The business’s fifty day moving average price is $9.22. Provention Bio Inc has a 12 month low of $1.52 and a 12 month high of $22.82. The company has a market cap of $448.32 million and a PE ratio of -10.08.
Hedge funds and other institutional investors have recently modified their holdings of the company. Silverleafe Capital Partners LLC bought a new position in Provention Bio during the first quarter valued at approximately $46,000. Lido Advisors LLC bought a new position in Provention Bio during the fourth quarter valued at approximately $47,000. Alambic Investment Management L.P. bought a new position in Provention Bio during the fourth quarter valued at approximately $29,000. BlackRock Inc. boosted its stake in Provention Bio by 26.4% during the fourth quarter. BlackRock Inc. now owns 26,235 shares of the company’s stock valued at $46,000 after buying an additional 5,472 shares during the last quarter. Finally, Vanguard Group Inc. bought a new position in Provention Bio during the third quarter valued at approximately $2,859,000. Hedge funds and other institutional investors own 1.77% of the company’s stock.
A number of analysts recently commented on PRVB shares. Zacks Investment Research cut G1 Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, May 16th. Chardan Capital initiated coverage on Provention Bio in a report on Monday, June 10th. They set a “buy” rating and a $20.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating on shares of ACASTI PHARM-TS in a report on Wednesday, June 26th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $12.19.
Provention Bio Company Profile
Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.
See Also: What is Call Option Volume?
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.